FTC, Surmodics and GTCR

FTC sues to block GTCR’s ‘unlawful acquisition’ of Surmodics
GTCR already owns the second largest medical device coatings manufacturer, Biocoat, and the FTC holds market monopoly concerns.
Surmodics drops after FTC files suit to block its planned sale to GTCR
Surmodics (NASDAQ:SRDX) fell 4.6% after the Federal Trade Commission filed a lawsuit to block its planned $627 million sale to private equity firm GTCR. The FTC filed suit in the U.S. District Court for the Northern District of Illinois,
FTC sues to block Surmodics acquisition by private equity over device coating competition
The FTC said merging Surmodics with Biocoat, where GTCR has a majority stake, would result in one company with more than 50% of the hydrophilic coating market.
FTC sues to block merger of device coatings companies
The Federal Trade Commission has filed a lawsuit to block private equity firm GTCR BC Holdings from acquiring Surmodics, a medical technology company, arguing the deal would reduce competition for critical device coatings.
FTC challenges private equity firm’s acquisition of Surmodics
The U.S. Federal Trade Commission (FTC) has sued to block the planned acquisition of medical device company Surmodics (Nasdaq:SRDX) by GTCR.
FTC Fights to Block Merger Threatening Healthcare Innovation and Patient-Critical Devices
The Federal Trade Commission (FTC) has filed a lawsuit seeking to block GTCR BC Holdings, LLC’s (GTCR) proposed acquisition of Surmodics, Inc., citing significant antitrust concerns. The
JD Supra2d
GTCR / Surmodics: Four Key Takeaways for M&A Antitrust from the First FTC Merger Challenge Under Trump
In the FTC’s first merger challenge of the new administration, the FTC voted 4-0 last week to challenge the proposed ...
Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR
Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, ...
Surmodics upgraded to Buy from Hold at Lake Street
Lake Street analyst Brooks O’Neil upgraded Surmodics (SRDX) to Buy from Hold with an unchanged price target of $43. The Federal Trade ...
JD Supra23h
FTC’s First Merger Challenge Under New Leadership Signals Return to Traditional Antitrust Theories in Private Equity Deals
On March 6, 2025, the Federal Trade Commission (FTC) filed a lawsuit in federal court challenging GTCR BC Holdings, LLC's (GTCR) proposed ...
Surmodics drops on report it will meet with regulators to try to save deal
Surmodics (NASDAQ:SRDX) edged lower by 0.7% amid a report that it's scheduled to meet with regulators this week to convince ...
Crain's Chicago Business7d
FTC targets GTCR in agency's first merger challenge under new Trump term
The regulator says the proposed merger would give the combined company more than 50% of the market for a type of medical ...
Fintel on MSN6d
Lake Street Upgrades Surmodics (SRDX)
Fintel reports that on March 7, 2025, Lake Street upgraded their outlook for Surmodics (NasdaqGS:SRDX) from Hold to Buy.
JD Supra22h
Client Alert: FTC Challenges Medical Device Coating Transaction
On March 7, 2025, the FTC filed a complaint in federal court seeking to block GTCR BC Holdings, LLC, a Chicago private equity firm, from ...